FDFT1 and small cell lung carcinoma: Similar results were obtained in several SCLC cell lines using a pharmacological FDFT1 inhibitor, lapaquistat, and an HMGCR inhibitor, atorvastatin (Fig. 5d and Supplementary Fig. 7c, d).